Internal Medicine, Endocrinology, Diabetes, & Metabolism · Brooklyn, NY
NPI
1023524600
Since 2017
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
101 Pennsylvania Avenue
Brooklyn, NY, 11207
Phone (718) 240-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$29K
358 services
Medicare patients, 2024
180
Average age 70
Drug cost, 2024
$2.5M
5,050 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Romana Kanta was code 99214 (office e&m - established), 213 times for 145 patients. In total Romana Kanta billed 358 services in 11 codes, and Medicare paid $29K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 213 | 145 | $101.53 | $22K |
| 99204 Office E&M - New | Office | 46 | 46 | $122.81 | $5,649 |
| 36415 Venipuncture Blood Collection | Office | 25 | 18 | $7.35 | $184 |
By year: 2022 $22K for 213 services; 2023 $23K for 283 services; 2024 $29K for 358 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 25 | 18 | $7.35 | $184 |
Medicare prescription drug claims, 2024
In 2024, the drug Romana Kanta prescribed most often to Medicare patients was Ozempic (Semaglutide), with 616 prescriptions and refills. In total Romana Kanta wrote 5,050 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 616 | 1,003 | 142 | $930K |
| Levothyroxine Sodium Generic | 371 | 1,049 | 145 | $5,540 |
| Novolog Flexpen Insulin Aspart | 364 | 737 | 146 | $112K |
| Jardiance Empagliflozin | 339 | 809 | 125 | $462K |
| Glimepiride Generic | 263 | 737 | 104 | $4,160 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 183 | 461 | 86 | $20K |
| Metformin Hcl Generic | 181 | 513 | 83 | $2,035 |
| Metformin Hcl Er Metformin Hcl | 175 | 430 | 75 | $2,955 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 167 | 448 | 81 | $26K |
| Methimazole Generic | 151 | 407 | 62 | $1,825 |
| Alendronate Sodium Generic | 134 | 350 | 45 | $1,476 |
| Repaglinide Generic | 131 | 348 | 50 | $4,691 |
| Glipizide Generic | 110 | 308 | 47 | $1,186 |
| Januvia Sitagliptin Phosphate | 100 | 240 | 40 | $126K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 100 | 285 | 41 | $39K |
Brand drugs: 2,526 claims; generic drugs: 1,993 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Romana Kanta were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.